The Cystic Fibrosis Foundation has awarded up to $3 million to Kinnear Pharmaceuticals to conduct preclinical testing of a broad-spectrum anti-infective that has the potential to treat multi-drug resistant Pseudomonas and other infections in people with cystic fibrosis.
Site Search
Showing 31 - 35 of 35 results
Press Release
|
|
3 min read
Press Release
|
|
2 min read
Program Aimed at Advancing Search for Therapies Targeting Most Common Mutation of CF
Press Release
|
|
3 min read
Press Release
|
|
3 min read
New Agreement Increases Potential Payments to EPIX by up to $37.7 Million
Press Release
|
|
6 min read